Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on November 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Dr. Eric Hughes resigning immediately as EVP, Global R&D and Chief Medical Officer.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. Eric Hughes resigning immediately as EVP, Global R&D and Chief Medical Officer
- Hughes remaining for several months to support transition
- Immediate leadership gap in R&D and medical oversight, potentially affecting drug development execution and pipeline strategy
Item 7.01 · Regulation FD Disclosure
- Dr. Eric Hughes will leave Teva, creating a senior leadership transition
- Departure details and succession plans are contained in Exhibit 99.1
- Investor focus: continuity of Teva’s strategic execution and medical leadership management
Item EX-99.1 · Exhibit EX-99.1
- R&D chief Eric Hughes departing for an external role, creating near-term leadership transition risk
- David Gardiner named interim R&D transition lead, reporting directly to CEO Richard Francis
- Permanent successor search begins immediately, making execution during the transition a key investor focus
- Teva reaffirmed its Pivot to Growth strategy and R&D priorities remain unchanged
- Innovative medicines revenue ambition remains $6–7 billion by 2030
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.